Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centrexion Therapeutics Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are handled by 2 distinct examiners across 2 distinct art units. This split means that each of the 2 pending office actions is being reviewed by a different individual. This distribution requires a separate prosecution strategy for each of the 2 pending office actions in the pharmaceutical sector.
HEASLEY, MEGHAN CHRISTINE is the busiest examiner with 1 pending office action. With 2 distinct examiners and 2 distinct art units, there is no concentration of oversight for the company's current pending matters. This lack of overlap requires a tailored approach for each of the 2 pending office actions. The company must navigate the specific requirements of 2 different art units to advance its current biotechnology portfolio. Each of the 2 pending office actions represents a unique technical hurdle in the life sciences. The resolution of these 2 pending office actions will define the company's immediate progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18947057 | CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAIN | HEASLEY, MEGHAN CHRISTINE | — |
| 18674288 | STABLE AQUEOUS CAPSAICIN INJECTABLE FORMULATIONS AND MEDICAL USES THEREOF | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947057 | CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAIN | HEASLEY, MEGHAN CHRISTINE | 1626 | §103Other | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18674288 | STABLE AQUEOUS CAPSAICIN INJECTABLE FORMULATIONS AND MEDICAL USES THEREOF | SZNAIDMAN, MARCOS L | 1628 | DP | Non-Final OA | — | Pending | May 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentrexion Therapeutics Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Meghan Christine Heasley has the most, with 1 of Centrexion Therapeutics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
